dc.contributor.author |
Otrock Z.K. |
dc.contributor.author |
Taher A.T. |
dc.contributor.author |
Shamseddeen W.A. |
dc.contributor.author |
Zaatari G. |
dc.contributor.author |
Bazarbachi A. |
dc.contributor.author |
Mahfouz R.A. |
dc.contributor.editor |
|
dc.date |
Dec-2008 |
dc.date.accessioned |
2017-10-05T15:59:22Z |
dc.date.available |
2017-10-05T15:59:22Z |
dc.date.issued |
2008 |
dc.identifier |
10.1007/s00277-008-0543-3 |
dc.identifier.isbn |
|
dc.identifier.issn |
09395555 |
dc.identifier.uri |
http://hdl.handle.net/10938/18968 |
dc.description.abstract |
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), occurs secondary to a number of hereditary and acquired disorders of hemostasis. A recently recognized polymorphism in Factor V (FV) gene H1299R (also named HR2) has been reported to be a possible risk factor for the development of VTE. The aim of this study is to evaluate the role of HR2 polymorphism in VTE in a group of Lebanese patients. Seventy-three VTE patients and 125 healthy subjects were examined for HR2. The average ages for the patients and controls were 45.0±19.1 years and 35.4±18.6 years, respectively. Sixty patients (82.2percent) had DVT, eight patients (11percent) had PE, and five patients (6.8percent) had both. There was significant association between FV Leiden and VTE (p0.001). HR2 haplotype had a prevalence of 16.4percent in patients. VTE patients with normal FV were 2.7 times more likely to have the HR2 haplotype as compared to controls with normal FV (p=0.036, 95percent CI=1.04-7.06). We conclude that the FV HR2 haplotype significantly affects the risk of VTE in subjects with normal FV. This finding entails that screening for the HR2 haplotype should be done in VTE patients with normal FV Leiden results. © Springer-Verlag 2008. |
dc.format.extent |
|
dc.format.extent |
Pages: (1013-1016) |
dc.language |
English |
dc.publisher |
NEW YORK |
dc.relation.ispartof |
Publication Name: Annals of Hematology; Publication Year: 2008; Volume: 87; no. 12; Pages: (1013-1016); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Factor V HR2 haplotype: A risk factor for venous thromboembolism in individuals with absence of Factor V Leiden |
dc.type |
Article |
dc.contributor.affiliation |
Otrock, Z.K., Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh 1107 2020, Beirut, Lebanon |
dc.contributor.affiliation |
Taher, A.T., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Shamseddeen, W.A., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Zaatari, G., Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh 1107 2020, Beirut, Lebanon |
dc.contributor.affiliation |
Bazarbachi, A., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Mahfouz, R.A., Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh 1107 2020, Beirut, Lebanon |
dc.contributor.authorAddress |
Mahfouz, R.A.; Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh 1107 2020, Beirut, Lebanon; email: rm11@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Pathology and Laboratory Medicine; |
dc.contributor.authorDepartment |
Pathology and Laboratory Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
rm11@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Otrock, ZK |
dc.contributor.authorInitials |
Taher, AT |
dc.contributor.authorInitials |
Shamseddeen, WA |
dc.contributor.authorInitials |
Zaatari, G |
dc.contributor.authorInitials |
Bazarbachi, A |
dc.contributor.authorInitials |
Mahfouz, RA |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Mahfouz, RA (reprint author), Amer Univ Beirut, Med Ctr, Dept Pathol and Lab Med, POB 11-0236,Riad El Solh 1107 2020, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P193; Benson JM, 2001, THROMB HAEMOSTASIS, V86, P1188; Bernardi F, 1997, BLOOD, V90, P1552; BERTINA RM, 1995, THROMB HAEMOSTASIS, V74, P449; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038-369064a0; Castaman G, 2003, HAEMATOLOGICA, V88, P1182; Castaman G, 1997, BRIT J HAEMATOL, V99, P257, DOI 10.1046-j.1365-2141.1997.3993213.x; Castoldi E, 2000, THROMB HAEMOSTASIS, V83, P362; DeStefano V, 1996, BLOOD, V87, P3531; Faioni EM, 1999, BLOOD, V94, P3062; Faioni EM, 2004, HAEMATOLOGICA, V89, P195; Jadaon MM, 2005, J THROMB HAEMOST, V3, P1467, DOI 10.1111-j.1538-7836.2005.01326.x; Kniffin W. D. Jr., 1994, Archives of Internal Medicine, V154, P861, DOI 10.1001-archinte.154.8.861; Koeleman BPC, 1997, SEMIN HEMATOL, V34, P256; Kostka H, 2003, BLOOD COAGUL FIBRIN, V14, P49, DOI 10.1097-01.mbc.0000046197.72384.42; Luddington R, 2000, THROMB HAEMOSTASIS, V83, P204; Lunghi B, 1996, THROMB HAEMOSTASIS, V75, P45; Margaglione M, 2002, THROMB HAEMOSTASIS, V87, P32; Pymar HC, 2001, SEMIN REPROD MED, V19, P305, DOI 10.1055-s-2001-18638; ROSING J, 1980, J BIOL CHEM, V255, P274; Simioni P, 2006, SEMIN THROMB HEMOST, V32, P700, DOI 10.1055-s-2006-951298; White RH, 2003, CIRCULATION S1, V107, pI4; Zaatari GS, 2006, PATHOLOGY, V38, P442, DOI 10.1080-00313020600922934 |
dc.description.citedCount |
7 |
dc.description.citedTotWOSCount |
6 |
dc.description.citedWOSCount |
6 |
dc.format.extentCount |
4 |
dc.identifier.articleNo |
|
dc.identifier.coden |
ANHEE |
dc.identifier.pubmedID |
18654780 |
dc.identifier.scopusID |
55649094889 |
dc.identifier.url |
|
dc.publisher.address |
233 SPRING ST, NEW YORK, NY 10013 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Ann. Hematol. |
dc.relation.ispartOfIssue |
12 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Annals of Hematology |
dc.relation.ispartofPubTitleAbbr |
Ann. Hematol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
87 |
dc.source.ID |
WOS:000260260400008 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Factor V Leiden |
dc.subject.otherAuthKeyword |
HR2 haplotype |
dc.subject.otherAuthKeyword |
Risk |
dc.subject.otherAuthKeyword |
Venous thromboembolism |
dc.subject.otherChemCAS |
arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3 |
dc.subject.otherChemCAS |
histidine, 645-35-2, 7006-35-1, 71-00-1 |
dc.subject.otherChemCAS |
factor V Leiden |
dc.subject.otherChemCAS |
Factor V, 9001-24-5 |
dc.subject.otherIndex |
arginine |
dc.subject.otherIndex |
blood clotting factor 5 Leiden |
dc.subject.otherIndex |
histidine |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
age distribution |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
deep vein thrombosis |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
genetic association |
dc.subject.otherIndex |
genetic polymorphism |
dc.subject.otherIndex |
genetic screening |
dc.subject.otherIndex |
haplotype |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
individuality |
dc.subject.otherIndex |
Lebanon |
dc.subject.otherIndex |
lung embolism |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
male |
dc.subject.otherIndex |
prevalence |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
venous thromboembolism |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Case-Control Studies |
dc.subject.otherIndex |
Exons |
dc.subject.otherIndex |
Factor V |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Genetic Predisposition to Disease |
dc.subject.otherIndex |
Haplotypes |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Lebanon |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Polymorphism, Single Nucleotide |
dc.subject.otherIndex |
Prevalence |
dc.subject.otherIndex |
Venous Thromboembolism |
dc.subject.otherKeywordPlus |
ACTIVATED PROTEIN-C |
dc.subject.otherKeywordPlus |
HR2 HAPLOTYPE |
dc.subject.otherKeywordPlus |
INHERITED THROMBOPHILIA |
dc.subject.otherKeywordPlus |
R2 ALLELE |
dc.subject.otherKeywordPlus |
THROMBOSIS |
dc.subject.otherKeywordPlus |
RESISTANCE |
dc.subject.otherKeywordPlus |
ASSOCIATION |
dc.subject.otherKeywordPlus |
POPULATION |
dc.subject.otherKeywordPlus |
MUTATION |
dc.subject.otherKeywordPlus |
COMPLEX |
dc.subject.otherWOS |
Hematology |